Rh-Catalyzed annulations of N-methoxybenzamides with ketenimines: synthesis of 3-aminoisoindolinones and 3-diarylmethyleneisoindolinones with strong aggregation induced emission properties
Structure–activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists
摘要:
In an effort to improve indole-based CB2 cannabinoid receptor ligands and also to develop SAR for both the CB1 and CB2 receptors, 47 indole derivatives were prepared and their CB1 and CB2 receptor affinities were determined. The indole derivatives include 1-propyl- and 1-pentyl-3-(1-naphthoyl)indoles both with and without a 2-methyl substituent. Naphthoyl substituents include 4- and 7-alkyl groups as well as 2-, 4-, 6-, 7-methoxy and 4-ethoxy groups. The effects of these substituents on receptor affinities are discussed and structure-activity relationships are presented. In the course of this work three new highly selective CB2 receptor agonists were identified, 1-propyl-3-(4-methyl-1-naphthoylindole (JWH-120), 1-propyl-2-methyl-3-(6-methoxy-1-naphthoylindole (JWH-151), and 1-pentyl-3-(2-methoxy-1-naphthoylindole (JWH-267). GTPgammaS assays indicated that JWH-151 is a full agonist at CB2, while JWH-120 and JWH-267 are partial agonists. Molecular modeling and receptor docking studies were carried out on a set of 3-(4-propyl-1-naphthoyl)indoles, a set of 3-(6-methoxy-1-naphthoyl)indoles and the pair of N-pentyl-3-(2-methoxy-1-naphthoyl)indoles. Docking studies indicated that the CB1 receptor affinities of these compounds were consistent with their aromatic stacking interactions in the aromatic microdomain of the CB1 receptor. (C) 2004 Elsevier Ltd. All rights reserved.
[EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD<br/>[FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE
申请人:ASTRAZENECA AB
公开号:WO2005115986A1
公开(公告)日:2005-12-08
Compounds of formulas I, IA, and IB or IC or pharmaceutically acceptable salts thereof: wherein A, A1, A2, A3, A4, R2, R3, R4 and n are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
Compounds of formula I or pharmaceutically acceptable salts thereof:
wherein R
1
, R
2
, R
3
, R
4
, n and A are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
Intramolecular Dehydrogenative Photocyclization of N-Phenyl-1-naphthamides
作者:Hao-Yuan Li、Xiaoying Niu、Shan-Shan Zhang、Shigang Shen、Qing-Yuan Meng、Xiu-Long Yang
DOI:10.1021/acs.orglett.4c01805
日期:2024.6.28
Here, we explore a dehydrogenative 6π photocyclization method for N-substituted naphthalene carboxamides, which can be conducted in air. This method employs DMSO as both the reaction solvent and oxidant while also stabilizing the excited state of the substrate. Furthermore, the addition of photosensitizer enables the reaction to proceed under a 440–445 nm LED source via energy transfer. The proposed
在这里,我们探索了一种N-取代萘甲酰胺的脱氢6π光环化方法,该方法可以在空气中进行。该方法采用DMSO作为反应溶剂和氧化剂,同时稳定底物的激发态。此外,光敏剂的添加使反应能够在 440-445 nm LED 光源下通过能量转移进行。所提出的机制最初通过 DFT 计算得到验证。
THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD
申请人:AstraZeneca AB
公开号:EP1756060A1
公开(公告)日:2007-02-28
DERIVES DE 1 ,2,4-TRIAZINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE HUMAINE